Speed, Scale, and Success: Why Rapid Bispecific Antibody Development Matters The Need for Speed in Drug Development With bispecific antibody innovation accelerating, speed has become a critical ...

A new dataset for predicting antigen-antibody interactions, published in the prestigious machine learning conference NeurIPS 2023, will help accelerate AI drug discovery KYOTO, Japan--(BUSINESS ...

Mathieu Bennet: In B-cell cloning, single-cell isolation occurs at two crucial stages. First, during the initial screening ...

Those tweaks may improve one property—how easily the antibody can be made at scale, for instance—but have a disastrous effect on the many other attributes required, such as selectivity ...

“We do not test different scale-up strategies for our projects, as our scale-up strategy is not influenced by the specific product being expressed. Whether the product is a standard IgG1 ...

STUTTGART, Germany I June 27, 2025 I La Merie Publishing announced the release of its newest technology market report about gene therapy technologies for in vivo expression of antibodies. The report ...

The development of their production processes is still challenging because of regulatory requirements and complex and sophisticated process strategies. Development and scale-up of cell culture ...

Archon Bioscience s, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding.The company aims to supercharge ...

The work, published today as a Reviewed Preprint in eLife, uses a high-throughput sequencing-based assay to quantify antibody immunity against circulating H3N2 flu strains in both children and adults.

Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune ...